Relative to 19del NSCLC, 21L858R disease is associated with more aggressive growth, higher rates of concomitant mutations, reduced EGFR-TKI sensitivity, and other distinct molecular characteristics [16–19]. Here, EGFR is linked to non-small cell lung carcinoma.